Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s.EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- ...
Cardiology, the branch of medicine concerned with the heart and blood vessels, has witnessed remarkable advancements in recent years that have transformed the field. These innovations have ...